- $489.43m
- $601.01m
- $297.18m
Brief: Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Evolus Announces Departure Of Its Chief Financial Officer
Brief: Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Evolus Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Evolus Q1 Product Revenue USD 68.074 Million
Brief: Evolus Inc - Enters New $250 Million Credit Facility With Pharmakon Advisors, Replacing Exisiting $125 Million Credit Agreement
Brief: Evolus reports inducement grants under Nasdaq listing rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Moderna, Hims & Hers Health, Carrier
Evolus rises on Q4 profit versus year-ago loss
Evolus Inc reports results for the quarter ended December 31 - Earnings Summary
Evolus rises after posting quarterly profit versus year-ago loss
Brief: Evolus Posts Q4 Net Revenue Of $79 Mln
Evolus posts quarterly profit on strong sales of cosmetic injection
Evolus rises on FDA nod for anti-wrinkle gels
US FDA approves Evolus' anti-wrinkle gels (updated)
US FDA approves Evolus' anti-wrinkle gels
U.S. STOCKS ON THE MOVE-Netflix, Reddit, L3Harris
U.S. STOCKS ON THE MOVE-Prologis, Space stocks, Evolus
Evolus rises after preliminary Q4 revenue beats estimates